Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters

Database
Language
Document Type
Year range
1.
Clin Case Rep ; 10(6): e05910, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1877569

ABSTRACT

Development of pemphigus foliaceus (PF) following SARS-CoV-2 infection has only been reported in one patient who had received Bamlanivimab and thus might be considered as a drug-induced case of PF. Here, we reported the first case of PF arising solely after COVID infection without taking any culprit drug.

3.
Dermatol Ther ; 35(6): e15433, 2022 06.
Article in English | MEDLINE | ID: covidwho-1735906

ABSTRACT

The prevalence of hair loss has increased during COVID-19. In this study, we review the current literature on incidence and characteristics of various types of COVID-19-related and COVID-19-vaccine- related hair loss including telogen effluvium, alopecia areata, friction alopecia and anagen effluvium. Regarding most of them, the more severe the infection, the more profound and prolonged the course of alopecia. However, the most important issue is reassuring the patients of the non-serious nature of this complication, since psychological support is the most important factor in the earlier resolution of the condition.


Subject(s)
Alopecia Areata , COVID-19 , Vaccines , Alopecia/complications , Alopecia Areata/epidemiology , COVID-19/prevention & control , Humans , SARS-CoV-2
4.
Dermatol Ther ; 35(5): e15430, 2022 05.
Article in English | MEDLINE | ID: covidwho-1731140

ABSTRACT

SARS-CoV2 vaccines were approved without long-term monitoring due to emergent situations. This has raised some issues about timing and protocol of receiving vaccines in specific situations including patients with chronic inflammatory disorders such as psoriasis. Here, we present different aspects of SARS-CoV-2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges. In brief, the benefits of vaccination outweigh the potential risk; vaccine-triggered de novo or flares of psoriasis is uncommon. As such, all psoriasis patients, especially those receiving systemic treatments including anti tumor necrosis factor agents, are strongly recommended to get SARS-CoV-2 vaccines. It is recommended that new immunosuppressive/immunomodulatory therapies be initiated at least 1 week after the second SARS-CoV-2 vaccine dose, if possible. In addition, in severe and active forms of psoriasis, it is better to delay vaccination until stabilization of the disease.


Subject(s)
COVID-19 , Psoriasis , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Humans , Psoriasis/drug therapy , RNA, Viral/therapeutic use , SARS-CoV-2 , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL